Opportunities for effective cervical cancer prevention

1. Дубровина С.О., Красильникова Л.В., Ардинцева О.А., Варичева М.В., Циркунова Н.С., Африкян О.А., Афанасова П.Н., Гаджибекова Н.Б. Влияние повидон-йода на эрадикацию высокоонкогенных типов ВПЧ у женщин с поражением шейки матки. РМЖ. Мать и дитя. 2018; 2: 159-61. [Dubrovina S.O., Krasilnikova L.V., Ardinceva O.A., Varicheva M.V., Tsircunova N.S., Afrikyan O. A., Afanasova P.N., Gadzhibekova N.B. Povidone-iodine effect on the eradication of highly oncogenic HPV types in women with lesions in the uterine cervix. Russian Medical Journal. 2018; 1(2): 159-160. (in Russian)] https://dx.doi.org/10.32364/2618-8430-2018-1-2-156-161.
2. Guo Y., You K., Qiao J., Zhao Y., Geng. L. Bacterial vaginosis is conducive to the persistence of HPV infection. Int. J. STD AIDS. 2012; 23(8): 581-4. https://dx.doi.org/10.1256/ijsa.2012.011242.
3. King C.C., Jamieson D.J., Wiener J., Cu-Uvin S., Klein R.S., Rompalo A.M. et al. Bacterial vaginosis and the natural history of human papillomavirus. Infect. Dis. Obstet. Gynecol. 2011; 2011: 319460. https://dx.doi.org/10.1155/2011/319460.
4. Gillet E., Meys J.F., Verstraelen H., Bosire C., De Sutter P., Temmerman M., Broeck D.V. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect. Dis. 2011; 11: 10. https://dx.doi.org/10.1186/1471-2334-11-10.
5. Gillet E., Meys J.F., Verstraelen H., Verhelst R., De Sutter P., Temmerman M., Broeck D.V. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One. 2012; 7(10): e45201. https://dx.doi.org/10.1371/journal.pone.0045201.
6. Lee J.E., Lee S., Lee H., Song Y.M., Lee K., Han M.J. et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One. 2013; 8(5): e63514. https://dx.doi.org/10.1371/journal.pone.0063514.
7. Mitra A., Maclntyre D.A., Lee Y.S., Smith A., Marchesi J.R., Lehne B. et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci. Rep. 2015; 5: 16865. https://dx.doi.org/10.1038/srep16865.
8. Motevaseli E., Shirzad M., Akrami S.M., Mousavi A.S., Mirsalehian A., Modarressi M.H. Normal and tumour cervical cells respond di erently to vaginal lactobacilli, independent of pH and lactate. J. Med. Microbiol. 2013; 62(7): 1065-72. https://dx.doi.org/10.1099/jmm.0.057521-0.
9. Brotman R.M., He X., Gajer P., Fadrosh D., Sharma E., Mongodin E.F. et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect. Dis. 2014; 14: 471. https://dx.doi.org/10.1186/1471-2334-14-471.
10. Arbyn M., Xu L., Simoens C., Martin-Hirsch P.P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst. Rev. 2018; (5): CD009069. https://dx.doi.org/10.1002/14651858.CD009069.pub3.
11. Зароченцева Н.В., Белая Ю.М., Джиджихия Л.К. Международные и отечественные результаты вакцинопрофилактики рака шейки матки и ВПЧ-ассоциированных заболеваний. Доктор. Ру. Гинекология Эндокринология. 2018; 2: 52-8. [Zarochentseva N.V., Belaya Y.M., Dzhidzhikhia L.K. Preventive Vaccination against cervical cancer and HPV-associated disorders: international and national date. Doctor.Ru. Gynecology. Endocrinology. 2018; 2(146): 52-58. (in Russian)]
12. Зароченцева Н.В., Белая Ю.М., Джиджихия Л.К. Вакцинопрофилактика рака шейки матки и заболеваний, ассоциированных с вирусом папилломы человека: вопросы и ответы. Российский вестник акушера-гинеколога. 2017; 17(5): 23-8. [Zarochentseva N.V., Belaya Y.M., Dzhidzhikhia L.K. Vaccinator prevention of cervical cancer and diseases associated with human papillomavirus: questions and answers. Rossiyskiyvestnikakushera-ginekologa. 2017; 17(5): 23-28. (in Russian)]
13. Luna J., Plata M., Gonzalez M., Correa A., Maldonado I., Nossa C. et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women. PLoS One. 2013; 8(12): e8343. https://dx.doi.org/10.1371/journal.pone.0083431.
14. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A. et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344: e1401. https://dx.doi.org/10.1136bmj.e1401.
15. Garland S.M., Paavonen J., Jaisamrarn U., Naud P., Salmerón J., Chow S.N. et al.; HPV PATRICIA Study Group. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high-grade cervicalintraepithelial neoplasia after definitive surgical therapy: post- hoc analysis from a randomized controlled trial. Int. J. Cancer. 2016; 139(12): 2812-26. https://dx.doi.org/ 10.1002 / ijc.30391.
16. Swedish K.A., Factor S.H., Goldstone S.E. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin. Infect. Dis. 2012; 54(7): 891-8. https://dx.doi.org/10.1093 / cid / cir1036.
17. Deshmukh A., Cantor S.B., Fenwick E., Chiao E.Y., Nyitray A.G., Strier E.A. et al. Adjuvant HPV vaccination for anal cancer preven- tion in HIV-positive men who have sex with men: the time is now. Vaccine. 2017; 35(38): 5102-9.https://dx.doi.org/10.1016 / j.vaccine.2017.08.006.
18. Kin Cho Goon P., Sholtz L.U., Sudhoff H. Recurrent respiratory papillomatosis (RRP) – time for a reckoning? Laryngoscope Investig. Otolaryngol. 2017; 2(4): 184-6. https://dx.doi.org/10.1002/lio2.80.
19. Swedish K.A., Goldstone S.E. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One. 2014; 9(4): e93393. https://dx.doi.org/10.1371 / journal.pone.0093393.
20. Ghelardi А., Parazzini F., Martella F., Pieralli F., Bay P., Tonetti A. et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol. Oncol. 2018; 151(2): 229-34. https://dx.doi.org/10.1016/j.ygyno.2018.08.033.
21. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G. et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine. 2012; 30(Suppl. 5): F88-99. https://dx.doi.org/10.1016/j.vaccine.2012.06.095.
22. Arbyn M., Redman C.W.E., Verdoodt F., Kyrgiou M., Tzafetas M., Ghaem-Maghami S. et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017; 18(12): 1665-79. https://dx.doi.org/10.1016/S1470-2045(17)30700-3.
23. Miroshnichenko G.G., Parva M., Holtz D.O., Klemens J.A., Dunton C.J. Interpretability of excisional biopsies of the cervix: cone biopsy and loop excision. J. Low. Genit. Tract Dis. 2009; 13(1): 10-2. https://dx.doi.org/10.1097/LGT.0b013e31817ff940.
24. Martin-Hirsch P.P., Paraskevaidis E., Bryant A., Dickinson H.O., Keep S.L. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2010; 16(6): CD001318. https://dx.doi.org/10.1002 / 14651858.CD001318.pub2.

Received 10.04.2019

Accepted 19.04.2019